Anadys Pharmaceuticals has initiated a Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin in patients with HCV.
The study will evaluate ANA598 in both treatment-naive patients and treatment-experienced patients who failed a prior course of therapy with interferon and ribavirin.
In the study, approximately 200 chronically infected genotype 1 hepatitis C patients will receive ANA598 in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP) (a current standard of care, or SOC), while 66 patients will receive placebo plus SOC.
The primary endpoint of the study will be sustained virological response 24 weeks (SVR24) after patients conclude all treatment.
ANA598 is the company’s direct-acting antiviral (DAA), being developed for the treatment of hepatitis C.